{"id":22759,"date":"2025-10-22T12:19:05","date_gmt":"2025-10-22T12:19:05","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=22759"},"modified":"2025-10-22T12:19:05","modified_gmt":"2025-10-22T12:19:05","slug":"innovent-biologics-teams-with-takeda-on-global-io-therapies","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/biotech\/innovent-biologics-teams-with-takeda-on-global-io-therapies\/","title":{"rendered":"\u30a4\u30ce\u30d9\u30f3\u30c8\u30fb\u30d0\u30a4\u30aa\u30ed\u30b8\u30af\u30b9\u304c\u6b66\u7530\u85ac\u54c1\u3068\u30b0\u30ed\u30fc\u30d0\u30ebIO\u6cbb\u7642\u85ac\u3067\u63d0\u643a"},"content":{"rendered":"<?xml encoding=\"utf-8\" ?><p>Innovent Biologics and Takeda are teaming up. This global partnership seeks to accelerate the development and launch of Innovent&rsquo;s new immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies. The partnership aims to provide groundbreaking cancer treatments to patients everywhere. It uses the combined skills of both companies.<\/p><p>The collaboration highlights three main investigational therapies from Innovent&rsquo;s IO+ADC pipeline. IBI363 is a first-in-class bispecific antibody fusion protein that targets PD-1 and IL-2&alpha;. It shows strong anti-tumor effects. It&rsquo;s a hopeful new therapy for immuno-oncology. IBI363 is now in global Phase 3 development. It targets second-line squamous non-small cell lung cancer (sqNSCLC). It has received Breakthrough Designation from China&rsquo;s NMPA and Fast Track Designation from the U.S. FDA. Innovent and Takeda will work together to develop IBI363 globally. They will split the development costs and market it together in the U.S. Takeda will manage sales outside Greater China and the U.S.<\/p><p>IBI343\u306fCLDN18.2\u3092\u6a19\u7684\u3068\u3059\u308bADC\u3002\u73fe\u5728\u3001\u80c3\u304c\u3093\u304a\u3088\u3073\u80c3\u98df\u9053\u304c\u3093\u3092\u5bfe\u8c61\u306b\u7b2c3\u76f8\u8a66\u9a13\u3092\u5b9f\u65bd\u4e2d\u3002\u3053\u308c\u307e\u3067\u306e\u3068\u3053\u308d\u3001\u6709\u671b\u306a\u5b89\u5168\u6027\u3068\u6709\u52b9\u6027\u3092\u793a\u3057\u3066\u3044\u307e\u3059\u3002\u30a4\u30ce\u30d9\u30f3\u30c8\u306f\u6b66\u7530\u85ac\u54c1\u306b\u958b\u767a\u30fb\u88fd\u9020\u30fb\u8ca9\u58f2\u306b\u95a2\u3059\u308b\u72ec\u5360\u7684\u306a\u5168\u4e16\u754c\u3067\u306e\u6a29\u5229\u3092\u4ed8\u4e0e\u3057\u307e\u3059\u3002\u305f\u3060\u3057\u3001\u5927\u4e2d\u83ef\u570f\u306f\u9664\u304d\u307e\u3059\u3002\u4e21\u793e\u306f\u3001IBI343\u3092\u80c3\u764c\u304a\u3088\u3073\u81b5\u764c\u306e\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u6cbb\u7642\u85ac\u3068\u3057\u3066\u4f7f\u7528\u3059\u308b\u3053\u3068\u3092\u76ee\u6307\u3057\u307e\u3059\u3002<\/p><h4>\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a <a class=\"p-url\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/biotech\/a-d-a-m-partners-with-sophia-for-liquid-biopsy-japan\/\" rel=\"bookmark\">A.D.A.M.\u3001\u30ea\u30ad\u30c3\u30c9\u30d0\u30a4\u30aa\u30d7\u30b7\u30fc\u3067SOPHiA\u793e\u3068\u63d0\u643a<\/a><\/h4><p>IBI3001\u306f\u3001EGFR\u3068B7-H3\u3092\u6a19\u7684\u3068\u3059\u308b\u30d5\u30a1\u30fc\u30b9\u30c8\u30fb\u30a4\u30f3\u30fb\u30af\u30e9\u30b9\u306e\u4e8c\u91cd\u7279\u7570\u6027ADC\u3067\u3042\u308a\u3001\u73fe\u5728\u3001\u81e8\u5e8a\u7b2c1\u76f8\u8a66\u9a13\u4e2d\u3067\u3059\u3002\u6b66\u7530\u85ac\u54c1\u306f\u3001\u5927\u4e2d\u83ef\u570f\u4ee5\u5916\u3067\u306e\u30b0\u30ed\u30fc\u30d0\u30eb\u3067\u306e\u72ec\u5360\u7684\u6a29\u5229\u3092\u53d6\u5f97\u3059\u308b\u3053\u3068\u3082\u53ef\u80fd\u3067\u3059\u3002\u305d\u306e\u5834\u5408\u3001\u958b\u767a\u3001\u88fd\u9020\u3001\u5546\u696d\u5316\u306e\u6a29\u5229\u304c\u542b\u307e\u308c\u307e\u3059\u3002<\/p><p>The partnership&rsquo;s financial structure features an upfront payment of US$1.2 billion from <a href=\"https:\/\/www.takeda.com\/\" data-no-translation=\"\">Takeda&nbsp;<\/a>\u3092\u30a4\u30ce\u30d9\u30f3\u30c8\u306b\u58f2\u5374\u3002\u3053\u308c\u306b\u306f\u3001\u30a4\u30ce\u30d9\u30f3\u30c8\u793e\u3078\u306e1\u5104US$\u306e\u682a\u5f0f\u6295\u8cc7\u304c\u542b\u307e\u308c\u307e\u3059\u3002\u30a4\u30ce\u30d9\u30f3\u30c8\u306f\u30013\u3064\u306e\u6cbb\u7642\u6cd5\u306e\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u3068\u3057\u3066\u6700\u5927US$102\u5104\u30c9\u30eb\u3092\u53d7\u3051\u53d6\u308b\u3053\u3068\u304c\u3067\u304d\u307e\u3059\u3002\u3053\u308c\u306b\u3088\u308a\u3001\u6f5c\u5728\u7684\u306a\u53d6\u5f15\u7dcf\u984d\u306f\u7d04US$114\u5104\u30c9\u30eb\u306b\u306a\u308a\u307e\u3059\u3002 <a href=\"https:\/\/www.innoventbio.com\/\" data-no-translation=\"\">Innovent Biologics<\/a> will also earn tiered royalties for each therapy outside Greater China. In the U.S., there&rsquo;s a profit-sharing deal for IBI363.<\/p><p>This collaboration helps both companies boost the global reach of Innovent&rsquo;s IO and ADC pipeline. It brings new treatment options to patients with great needs in oncology. It also boosts their commitment to improve precision cancer care around the globe.<\/p>","protected":false},"excerpt":{"rendered":"<p>Innovent Biologics and Takeda are teaming up. This global partnership seeks to accelerate the development and launch of Innovent&rsquo;s new immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies. The partnership aims to provide groundbreaking cancer treatments to patients everywhere. It uses the combined skills of both companies.The collaboration highlights three main investigational therapies from Innovent&rsquo;s IO+ADC pipeline. IBI363 is a first-in-class bispecific antibody fusion protein that targets PD-1 and IL-2&alpha;. It shows strong anti-tumor effects. It&rsquo;s a hopeful new therapy for immuno-oncology. IBI363 is now in global Phase 3 development. It targets second-line squamous non-small cell lung cancer (sqNSCLC). It has received Breakthrough Designation from China&rsquo;s NMPA and Fast Track Designation [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":22760,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[208,181,89,211,237,206],"tags":[8698,150,8699,8697,8700],"ppma_author":[572],"class_list":["post-22759","post","type-post","status-publish","format-standard","has-post-thumbnail","category-apac","category-biotech","category-health-tech","category-japan","category-news","category-regional","tag-adc-molecules","tag-biotech","tag-innovent-biologics","tag-io-backbone-therapy","tag-takeda"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innovent and Takeda Join for Global IO Therapy Rollout<\/title>\n<meta name=\"description\" content=\"Innovent Biologics with Takeda to advance next-gen IO and ADC cancer therapies, aiming to deliver transformative treatments globally.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/biotech\/innovent-biologics-teams-with-takeda-on-global-io-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent and Takeda Join for Global IO Therapy Rollout\" \/>\n<meta property=\"og:description\" content=\"Innovent Biologics with Takeda to advance next-gen IO and ADC cancer therapies, aiming to deliver transformative treatments globally.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/biotech\/innovent-biologics-teams-with-takeda-on-global-io-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-22T12:19:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Innovent-Biologics-Announces-Global-Strategic-Partnership-with-Takeda-to-Bring-Innovents-Next-Gen-IO-Backbone-Therapy-and-ADC-Molecules-to-the-Global-Market.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"ITBT StaffWriter\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ITBT StaffWriter\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30a4\u30ce\u30d9\u30f3\u30c8\u793e\u3068\u6b66\u7530\u85ac\u54c1\u304cIO\u7642\u6cd5\u306e\u30b0\u30ed\u30fc\u30d0\u30eb\u5c55\u958b\u3067\u63d0\u643a","description":"\u30a4\u30ce\u30d9\u30f3\u30c8\u30fb\u30d0\u30a4\u30aa\u30ed\u30b8\u30af\u30b9\u793e\u304c\u6b66\u7530\u85ac\u54c1\u3068\u6b21\u4e16\u4ee3IO\u304a\u3088\u3073ADC\u304c\u3093\u6cbb\u7642\u85ac\u306e\u958b\u767a\u3067\u63d0\u643a\u3001\u9769\u65b0\u7684\u306a\u6cbb\u7642\u3092\u30b0\u30ed\u30fc\u30d0\u30eb\u306b\u63d0\u4f9b\u3078.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/biotech\/innovent-biologics-teams-with-takeda-on-global-io-therapies\/","og_locale":"ja_JP","og_type":"article","og_title":"Innovent and Takeda Join for Global IO Therapy Rollout","og_description":"Innovent Biologics with Takeda to advance next-gen IO and ADC cancer therapies, aiming to deliver transformative treatments globally.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/biotech\/innovent-biologics-teams-with-takeda-on-global-io-therapies\/","og_site_name":"itbusinesstoday","article_published_time":"2025-10-22T12:19:05+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Innovent-Biologics-Announces-Global-Strategic-Partnership-with-Takeda-to-Bring-Innovents-Next-Gen-IO-Backbone-Therapy-and-ADC-Molecules-to-the-Global-Market.webp","type":"image\/webp"}],"author":"ITBT StaffWriter","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"ITBT StaffWriter","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/innovent-biologics-teams-with-takeda-on-global-io-therapies\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/innovent-biologics-teams-with-takeda-on-global-io-therapies\/"},"author":{"name":"ITBT StaffWriter","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15"},"headline":"Innovent Biologics teams with Takeda on global IO therapies","datePublished":"2025-10-22T12:19:05+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/innovent-biologics-teams-with-takeda-on-global-io-therapies\/"},"wordCount":384,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/innovent-biologics-teams-with-takeda-on-global-io-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Innovent-Biologics-Announces-Global-Strategic-Partnership-with-Takeda-to-Bring-Innovents-Next-Gen-IO-Backbone-Therapy-and-ADC-Molecules-to-the-Global-Market.webp","keywords":["ADC Molecules","Biotech","Innovent Biologics","IO Backbone Therapy","Takeda"],"articleSection":["APAC","Biotech","Health Tech","Japan","News","Regional"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/innovent-biologics-teams-with-takeda-on-global-io-therapies\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/innovent-biologics-teams-with-takeda-on-global-io-therapies\/","name":"\u30a4\u30ce\u30d9\u30f3\u30c8\u793e\u3068\u6b66\u7530\u85ac\u54c1\u304cIO\u7642\u6cd5\u306e\u30b0\u30ed\u30fc\u30d0\u30eb\u5c55\u958b\u3067\u63d0\u643a","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/innovent-biologics-teams-with-takeda-on-global-io-therapies\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/innovent-biologics-teams-with-takeda-on-global-io-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Innovent-Biologics-Announces-Global-Strategic-Partnership-with-Takeda-to-Bring-Innovents-Next-Gen-IO-Backbone-Therapy-and-ADC-Molecules-to-the-Global-Market.webp","datePublished":"2025-10-22T12:19:05+00:00","description":"\u30a4\u30ce\u30d9\u30f3\u30c8\u30fb\u30d0\u30a4\u30aa\u30ed\u30b8\u30af\u30b9\u793e\u304c\u6b66\u7530\u85ac\u54c1\u3068\u6b21\u4e16\u4ee3IO\u304a\u3088\u3073ADC\u304c\u3093\u6cbb\u7642\u85ac\u306e\u958b\u767a\u3067\u63d0\u643a\u3001\u9769\u65b0\u7684\u306a\u6cbb\u7642\u3092\u30b0\u30ed\u30fc\u30d0\u30eb\u306b\u63d0\u4f9b\u3078.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/innovent-biologics-teams-with-takeda-on-global-io-therapies\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/biotech\/innovent-biologics-teams-with-takeda-on-global-io-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/innovent-biologics-teams-with-takeda-on-global-io-therapies\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Innovent-Biologics-Announces-Global-Strategic-Partnership-with-Takeda-to-Bring-Innovents-Next-Gen-IO-Backbone-Therapy-and-ADC-Molecules-to-the-Global-Market.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Innovent-Biologics-Announces-Global-Strategic-Partnership-with-Takeda-to-Bring-Innovents-Next-Gen-IO-Backbone-Therapy-and-ADC-Molecules-to-the-Global-Market.webp","width":1200,"height":800,"caption":"Innovent Biologics"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/innovent-biologics-teams-with-takeda-on-global-io-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Innovent Biologics teams with Takeda on global IO therapies"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15","name":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png90b3cb23d1d9c08733d969d29ea2d30d","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","caption":"ITBT StaffWriter"},"description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002","sameAs":["https:\/\/itbusinesstoday.com\/"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/itbt-staffwriter\/"}]}},"authors":[{"term_id":572,"user_id":7,"is_guest":0,"slug":"itbt-staffwriter","display_name":"ITBT StaffWriter","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png"},"author_category":"","first_name":"ITBT","last_name":"StaffWriter","user_url":"https:\/\/itbusinesstoday.com\/","job_title":"","description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002"}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/22759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=22759"}],"version-history":[{"count":2,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/22759\/revisions"}],"predecessor-version":[{"id":22776,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/22759\/revisions\/22776"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/22760"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=22759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=22759"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=22759"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=22759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}